Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 10/20 | 1.00 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | PDE5A | O76074 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899543 | 0.86 | CYP2D6 (0.75) | CYP2D6CYP1A2SCN8ACYP3A4PDE5A | |
| SCHEMBL13865213 | 0.84 | CYP2D6 (0.72) | CYP2D6CYP1A2SCN8ACYP3A4PDE5A | |
| Dimethylamine SCHEMBL1899545 | 0.81 | CYP2D6 (0.67) | CYP2D6CYP1A2SCN8ACYP3A4PDE5A | |
| SCHEMBL13583832 | 0.80 | CYP2D6 (0.66) | CYP2D6CYP1A2SCN8ACYP3A4PDE5A | |
| SCHEMBL1768299 | 0.76 | SCN8A (0.69) | CYP2D6CYP1A2SCN8ACYP3A4LMNA | |
| SCHEMBL13865176 | 0.73 | PDE5A (0.62) | CYP2D6CYP1A2SCN8ACYP3A4PDE5A | |
| SCHEMBL3071869 | 0.73 | PDE5A (0.77) | CYP2D6CYP1A2SCN8ACYP3A4PDE5A | |
| SCHEMBL3621787 | 0.73 | ALDH1A1 (0.67) | CYP2D6CYP1A2SCN8ACYP3A4PDE5A | |
| SCHEMBL13865190 | 0.73 | CYP2D6 (0.57) | CYP2D6CYP1A2SCN8ACYP3A4PDE5A | |
| SCHEMBL7493020 | 0.72 | CYP2D6 (0.57) | CYP2D6CYP1A2SCN8ACYP3A4PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | claimed |
| EP-1252156-B1 | BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS | UCL BUSINESS PLC (GB) | 2011-05-04 | — | — | EP | disclosed |
| US-7790761-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2010-09-07 | — | — | US | disclosed |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | GARTHWAITE GITI | 2006-05-11 | — | — | US | disclosed |
| US-7009056-B2 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2006-03-07 | — | — | US | disclosed |
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | UNIVERSITY COLLEGE LONDON (GB) | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171403-A1 | Blockade of voltage dependent sodium channels | CACNA1F, SCNN1B, CACNA1B | CYP2D6 3055/4885CYP1A2 2320/4885SCN8A 51/4885 |
| US-20060100248-A1 | Blockade of voltage dependent sodium channels | CACNA1I, CACNA1F, CACNA1C | CYP2D6 3045/4885CYP1A2 2317/4885SCN8A 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.